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Abstract   
 
Fibroblast growth factor (FGF23) plasma levels are elevated in cardiac and renal failure, and 
correlate with poor clinical prognosis of those disorders. Both disorders are associated with 
hyperaldosteronism. An excessive FGF23 level and hyperaldosteronism are further observed in 
Klotho-deficient mice. The present study explored a putative aldosterone sensitivity of FGF23 
transcription and secretion and the putative involvement of transcription factor NFκB, which is 
known to upregulate Orai1, the Ca2+ channel accomplishing store operated Ca2+ entry (SOCE). 
Serum FGF23 levels were determined by ELISA in mice with or without deoxycorticosterone 
acetate (DOCA) treatment or salt depletion. In osteoblastic cells (UMR106) and immortalized 
primary periosteal (IPO) cells protein abundance was determined by Western blotting, and in 
UMR106 cells transcript levels were quantified by RT-PCR, cytosolic Ca2+-activity utilizing 
Fura-2-fluorescence, and SOCE from Ca2+ entry following store depletion by thapsigargin. As a 
result, DOCA treatment and salt depletion of mice elevated the serum C-terminal FGF23 
concentration. In UMR106 cells aldosterone increased Fgf23 transcript levels, an effect reversed 
by mineralocorticoid receptor blockers spironolactone and eplerenone, NFκB-inhibitor 
withaferin A, and Ca2+-channel blocker YM58483. Aldosterone enahnced and spironolactone 
decreased Ca2+ entry in UMR106 cells. UMR106 and IPO cells expressed Ca2+-channel Orai1. 
SOCE was lowered by NFκB inhibitor wogonin and blunted by Orai1 inhibitors 2-APB and 
YM58483. UMR106 cell Fgf23 transcripts were increased by stimulation of SOCE and Ca2+ 
ionophore ionomycin and decreased by Orai inhibitors, by Orai1 silencing, as well as NFκB 
inhibitors wogonin and withaferin A. In conclusion, Fgf23 expression is up-regulated by 
aldosterone and stimulation of NFκB-sensitive, store-operated Ca2+ entry.  
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Introduction 
 
 FGF23 (fibroblast growth factor 23), a hormone released mainly from bone, is a 
powerful regulator of calcium phosphate metabolism [1]. FGF23 down-regulates renal 1α 
hydroxylase (Cyp27b1) and up-regulates 25-hydroxyvitamin D 24-hydroxylase (Cyp24a1) 
thus reducing the formation and enhancing the inactivation of 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3) [2]. As a result, FGF23 decreases the serum level of 1,25(OH)2 D3  [3, 4]. 
1,25(OH)2 D3  is in turn a powerful regulator of renal and intestinal phosphate and calcium 
transport [5, 6]. In addition to its effect on 1,25(OH)2D3  formation, FGF23 directly decreases 
renal tubular phosphate reabsorption [3] and thus stimulates renal phosphate elimination [3]. 
FGF23 deficiency results in elevated serum phosphate, calcium and 1,25(OH)2D3 levels with 
excessive vascular calcifications, rapid aging and a profound decrease of lifespan [2]. 
The effect of FGF23 on 1,25(OH)2D3 formation requires αKlotho as a co-receptor [7, 
8]. Mice lacking functional αKlotho similarly suffer from extensive vascular calcifications, 
early onset of multiple age-related disorders and severe shortening of life span [8]. Similar to 
FGF23 deficiency, αKlotho deficiency is effective mainly through excessive 1,25(OH)2D3 
formation, enhanced renal tubular phosphate reabsorption and increased serum phosphate 
levels [9]. As a matter of fact, hyperphosphatemia fosters vascular calcification [10] and is 
considered a predictor of mortality [11]. FGF23 plasma levels are extremely high in Klotho 
deficient mice, a result at least in part due to excessive 1,25(OH)2D3 levels, but again paralleled 
by hyperaldosteronism [12, 13].  
The pathophysiological role of FGF23 has, however, remained enigmatic [14, 15]. In 
patients with cardiac failure [16, 17], acute renal failure [18], chronic kidney disease [7, 17, 19], 
diabetic nephropathy [20] and hepatic failure [21], plasma FGF23 concentrations are high and 
associated with accelerated disease progression, morbidity and/or mortality. Mechanisms 
up-regulating FGF23 in those disorders are still ill-defined. 
Known regulators of FGF23 release include 1,25(OH)2D3 [7], αKlotho [22, 23], PHEX 
(phosphate-regulating gene with homology to endopeptidase), DMP-1 (dentin matrix protein or 
cyclin D binding myb-like protein 1), sustained phosphate load even without 
hyperphosphatemia, a high extracellular Ca2+ concentration, and PTH [7, 24]. FGF23 plasma 
levels are further modified by iron deficiency [25, 26], pregnancy [27] and FGF23 secreting 
tumors [28]. 
To the best of our knowledge, nothing is known about a role of the cytosolic Ca2+ 
concentration ([Ca2+]i) in FGF23 expression. In some cell types Ca2+ may enter through SOCE, 
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i.e. store-operated Ca2+ entry, which is stimulated by intracellular Ca2+ store depletion [29]. 
SOCE is accomplished by the 4-transmembrane-spanning pore forming calcium 
release-activated channel (CRAC) moiety Orai1 (CRACM1) [30], and its regulator stromal 
interaction molecule 1 (STIM1), which senses the Ca2+ content of the endoplasmic reticulum 
(ER) [31]. The expression of Orai1 has previously been shown to be regulated by nuclear 
transcription factor NFκB [32].   
Regulators of NFκB include mineralocorticoids [33, 34]. In patients with non-ischemic 
cardiac disease and early chronic kidney disease high FGF23 plasma levels are associated with 
high plasma aldosterone concentrations [17]. 
The present study explored whether aldosterone modifies FGF23 release and, if so, 
whether the effect involves NFκB-sensitive Ca2+ entry.  
 
 
Materials and Methods 
 
Animal experiments 
 The animal experiments were conducted according to the German law for the welfare of 
animals and were approved by the state of Baden-Württemberg (Regierungspräsidium). To 
study the direct effect of mineralocorticoids on FGF23 release in vivo, 50 µl blood was 
collected from male and female C57BL/6 mice (8-20 weeks old). Then, mice were treated with 
a single s.c. injection of deoxycorticosterone acetate (DOCA; 100 mg/kg b.w.; Sigma, 
Schnelldorf, Germany) or spironolactone (75 mg/kg b.w.; Sigma) or sham-treated. Twelve 
hours after the injection, another 50 µl blood was collected. For the effect of the low salt diet on 
FGF23 release, male and female mice (2-13-month-old) were fed a control diet or a low salt diet 
(containing <0.2% Na+ and Cl-; Altromin, Lage, Germany) for a total of 7-14 days and 
subsequently 50 µl blood were collected. Serum C-terminal FGF23 was determined with an 
ELISA kit (Immutopics, San Clemente, USA). Serum aldosterone and corticosterone were 
quantified by means of kits from IBL (Hamburg, Germany) according to the manufacturers’ 
protocol.  
 
Cell culture 
UMR106 rat osteosarcoma cells were cultured in DMEM high glucose medium 
supplemented with 10% FCS and 1% penicillin/streptomycin under standard culture 
conditions. Human immortalized primary periosteal cells (IPO) were cultured in DMEM F-12 
 
 
5 
 
(1:1 mixture of DMEM and Ham's F-12, high glucose) containing Glutamax and 10% FCS and 
1% penicillin/streptomycin/1% fungizide. 
Cells were pretreated with 100 nM 1,25(OH)2D3 (Sigma, Schnelldorf, Germany). After 
24 h cells were in addition treated with 50 μM Orai inhibitor 2-APB (TOCRIS, Bristol, UK), 
100 nM Orai inhibitor YM58483 (TOCRIS), 10 μM Orai inhibitor SK&F96365 (TOCRIS), 
500 nM NFκB inhibitor withaferin A (TOCRIS), or NFκB inhibitor CAS 545380-34-5 (EMD) 
for another 24 h or treated with vehicle only. Cells pretreated with 100 nM 1,25(OH)2D3 for 46 
h were incubated with or without 100 nM ionomycin (Sigma) or 500 nM thapsigargin (Sigma) 
for 2 h. Alternatively, cells were incubated with or without 100 µM NFκB inhibitor wogonin 
(Sigma). After 24 h, 1,25(OH)2D3 (100 nM) was added, and cells were analyzed after another 
24 h. For some experiments, cells were pretreated with 100 nM 1,25(OH)2D3 for 42 h. Then, 
100 nM aldosterone (Sigma) was added without or with 10 µM spironolactone, 10 µM 
eplerenone, 100 nM YM58483, 500 nM withaferin A, or 50 µM SGK1 inhibitor EMD638683 
(Merck Darmstadt, Germany) for 6 h. 
For the calcium measurements and the quantification of Orai1 transcripts, cells were 
treated with 100 nM aldosterone (Sigma) or 10 μM spironolactone (Sigma) for 24 h in 
serum-free medium. Where indicated, experiments were performed in the presence of 
nifedipine (100 µM) or verapamil (10 µM) (both from Sigma). 
 
Silencing 
For silencing, 1 x 105 cells (12-well plate) and 2 x 105 cells (6-well plate) were seeded 
24 h before the experiment in antibiotic-free medium. Cells were transfected with 5 µl/1000 µl 
ON-TARGETplus RAT Orai1 siRNA (5 µM, Thermo Fisher Scientific, Waltham, MA, USA) 
and ON-TARGETplus Non-targeting siRNA (5 µM, Thermo Fisher Scientific) using the 
cationic lipid DharmaFECT 1 transfection reagent (0.5 µl/1000 µl, Thermo Fisher Scientific) 
according to the manufacturer’s protocol. Twenty-four hours after transfection, cells were 
treated with 1,25(OH)2D3 (100 nM) for another 24 h. Cells were then harvested and analyzed. 
To verify silencing efficiency, the Orai1 transcript level was quantified. As a result, the Orai1 
mRNA level was 0.33 ± 0.05 a.u. (n=16) in cells transfected with a negative control siRNA and 
0.13 ± 0.01 a.u. (n=16), p<0.001 in cells transfected with a negative control siRNA. 
 
Quantification of mRNA expression 
For the mRNA expression analysis in UMR106 cells, the final volume of the RT-PCR 
reaction mixture was 15 µl and contained: 1 µl cDNA, 1 µM of each primer, 7.5 µl GoTaq 
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Master Mix Green (Promega), and sterile water up to 15 µl. PCR conditions were 95°C for 3 
min, followed by 40 cycles of 95°C for 10 s, 58°C for 30 s and 72°C for 45s. The product size 
was analyzed on a 2% agarose gel. Quantitative RT-PCR was performed on a BioRad iCycler 
iQTM Real-Time PCR Detection System (Bio-Rad Laboratories, München, Germany). 
For the determination of Fgf23 transcripts in mouse bone, bone was homogenized in 
liquid nitrogen using mortar and pestle. Total mRNA from bone was extracted with TRIzol 
(Invitrogen, Switzerland) followed by purification with RNeasy Mini Kit (Qiagen, 
Switzerland) according to the manufacturer’s protocol. DNAse digestion was performed using 
the RNase-free DNAase Set (Qiagen, Switzerland). Total RNA extractions were analyzed for 
quality, purity, and concentration using the NanoDrop ND-1000 spectrophotometer 
(Wilmington, Germany). RNA samples were diluted to a final concentration of 100 ng/µl and 
cDNA was prepared using the TaqMan Reverse Transcriptase Reagent Kit (Applied 
Biosystems, Roche, Foster City, CA). In brief, in a reaction volume of 40 µl, 300 ng of RNA 
was used as template and mixed with the following final concentrations of RT buffer (1x): 
MgCl2 (5.5 mmol/l), random hexamers (2.5 µmol/l), dNTP mix (500 µmol/l each), RNase 
inhibitor (0.4 U/µl), multiscribe reverse transcriptase (1.25 U/µl), and RNAse-free water. 
Reverse transcription was performed with thermocycling conditions set at 25°C for 10 min, 
48°C for 30 min, and 95°C for 5 min on a thermocycler (Biometra, Göttingen, Germany). 
Quantitative realtime PCR (RT-PCR) was performed on the ABI PRISM 7700 Sequence 
Detection System (Applied Biosystems). Primers were chosen to spanning intron–exon 
boundaries to exclude genomic DNA contamination. The specificity of all primers was tested 
and always resulted in a single product of the expected size (data not shown). Probes were 
labeled with the reporter dye FAM at the 5’-end and the quencher dye TAMRA at the 3’-end 
(Microsynth, Balgach, Switzerland). Real-time PCR reactions were performed using KAPA 
PROBE FAST qPCR Kit (KappaBiosystems, USA). 
The following primers were used: 
Rat Tbp (TATA box-binding protein): 
forward (5'-3'): ACTCCTGCCACACCAGCC 
reverse (5'-3'): GGTCAAGTTTACAGCCAAGATTCA 
Rat Fgf23 
forward (5'-3'): TGGCCATGTAGACGGAACAC 
reverse (5'-3'): GGCCCCTATTATCACTACGGAG 
Rat Orai1 
forward (5'-3'): CGTCCACAACCTCAACTCC 
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reverse (5'-3'): AACTGTCGGTCCGTCTTAT 
Rat Orai2 
forward (5'-3'): GGAAGCCGTGAGCAACAT 
reverse (5'-3'): CACCAGGGAGCGGTAGAA 
Rat Orai3 
forward (5'-3'): TTTTGGTGGGCTGGGTCA 
reverse (5'-3'): TCCTGCTTGTGGCGGTCT 
Rat Stim1 
forward (5'-3'): CGTCCGCAACATCCACAAG 
reverse (5'-3'): CCATAGGTCCTCCACGCT 
Rat Stim2  
forward (5'-3'): ACTTAGAAAGCCTACAAACCG 
reverse (5'-3'): GCATCAGGGACAGACCAG 
Rat Sgk1 
forward (5'-3'): ATGTGAAGCACCCTTTCCTG 
reverse (5'-3'): TAGAACAGCTCTCCGCCATT 
Mouse Fgf23 
forward (5'-3'): TCGAAGGTTCCTTTGTATGGAT 
reverse (5'-3'): AGTGATGCTTCTGCGACAAGT 
Calculated mRNA expression levels were normalized to the expression levels of Tbp (in rat 
derived cell lines) or HPRT/18S (in mice) of the same cDNA sample. Relative quantification of 
gene expression was performed using the ΔΔCt method. 
 
Western blotting 
Orai1 protein abundance was determined in UMR106 cells, IPO cells, and mouse bone 
(femur). The cells were washed in ice-cold PBS. For bone preparation, a mouse was sacrificed 
and the femur isolated. Muscles were carefully removed and the femur snap-frozen. After 
thawing, the epiphyses were removed and the bone marrow was flushed out with ice-cold PBS. 
Using a mortar and pestle, the bone was pulverized on dry ice. RIPA lysis buffer (Cell 
Signaling, Frankfurt, Germany) containing phosphatase and protease inhibitor cocktail tablet 
(Complete mini, Roche, Mannheim, Germany) was added to the washed cells or the bone 
powder. The samples were incubated on ice for 30 min and then centrifuged at 14,000 rpm and 
4°C for 20 min. The supernatant was removed and used for Western blotting. Total protein 
(40-60 µg) was separated by SDS-PAGE, thereafter transferred to PVDF membranes and 
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blocked in 5% non-fat milk/Tris-buffered saline/Tween-20 (TBST) at room temperature for 1 
hour. Membranes were probed overnight at 4ºC with polyclonal rabbit anti-Orai1 antibody 
(1:700 in 5% BSA in TBST; Proteintech, Manchester, UK). After incubation with horseradish 
peroxidase-conjugated anti-rabbit secondary antibody (Cell Signaling, Frankfurt, Germany; 
1:2000) for 1 hour at room temperature, the bands were visualized with enhanced 
chemiluminescence reagents (Amersham, Freiburg, Germany). Membranes were also probed 
with GAPDH antibody (Cell signaling, 1:2000) as loading control. Densitometric analysis was 
performed using quantity One software (Bio-Rad, München, Germany). 
 
Measurement of intracellular Ca2+ 
To determine the cytosolic Ca2+ concentration ([Ca2+]i), UMR106 cells were loaded 
with Fura-2/AM (2 µM, Molecular Probes, Göttingen, Germany) for 15 min at 37°C. 
Fluorescence measurements were carried out with an inverted phase-contrast microscope 
(Axiovert 100, Zeiss, Oberkochen, Germany). Cells were excited alternatively at 340 or 380 nm 
and the light was deflected by a dichroic mirror into either the objective (Fluar 40×/1.30 oil, 
Zeiss, Oberkochen, Germany) or a camera (Proxitronic, Bensheim, Germany). Emitted 
fluorescence intensity was recorded at 505 nm. Data acquisition was accomplished by using 
specialized computer software (Metafluor, Universal Imaging Downingtown, USA). As a 
measure for the increase in the cytosolic Ca2+ concentration, the slope and peak of the changes 
in the 340/380 nm ratio were determined in each experiment.  
To determine SOCE, intracellular Ca2+ was measured before and after removal of 
extracellular Ca2+ (and addition of 0.5 mM EDTA), followed by addition of thapsigargin (1 
µM) and subsequent readdition of extracellular Ca2+ to Ringer solution, composed of (in mM): 
125 NaCl, 5 KCl, 1.2 MgSO4, 32.2 HEPES, 2 Na2HPO4, 0 or 2 CaCl2 and 0.5 or 0 EGTA, 
respectively, and 5 glucose, pH 7.4 (NaOH).  
 
Immunofluorescence 
UMR106 cells treated with 100 nM aldosterone were cultured on 4-well chamber slides 
(Thermo scientific), washed, and fixed with 4% paraformaldehyde for 30 min at room 
temperature. For blocking unspecific bindings, UMR106 cells were incubated with 3% 
Albumin Fraction V (Carl Roth, Karlsruhe, Germany), 5% normal goat serum (Sigma, 
Schnelldorf, Germany), and 0.5% Triton in PBS (PAA, Cölbe, Germany) for 30 min at room 
temperature. Then, the cells were exposed to rabbit anti-p65 (1:1000, Genetex, Irvine, USA) at 
4°C in a humidified chamber overnight. The cells were rinsed four times with PBS and 
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incubated with DyLight® 488-conjugated goat anti-rabbit antibody (1:3000, BIOZOL, Eching, 
Germany) for 1 h at room temperature. After four washing steps the nuclei were stained with 
DRAQ-5 dye (1:400; BIOZOL) for 30 min at room temperature. The slides and coverslips were 
mounted with FluorSaveTM Reagent (Calbiochem, Darmstadt, Germany). Images were taken on 
a LSM 5 EXCITER confocal laser scanning microscope (Zeiss, Germany) with a 
water-immersion Plan-Neofluar 40×/1.3 NA differential interference contrast and analyzed 
with the instrument's software. 
 
Statistics 
 Data are provided as means ± SEM, n represents the number of independent 
experiments. All data were tested for significance using unpaired Student t-test or ANOVA. 
Only results with p < 0.05 were considered statistically significant. 
 
 
Results 
 
 The present study explored whether FGF23 release is triggered by mineralocorticoids, 
and, if so, whether the effect involves NFκB-sensitive Ca2+ signaling.  
 In order to test for an effect of mineralocorticoids on FGF23 release, a single dose of 
DOCA (100 mg/kg b.w. s.c.) or vehicle was injected into wild type mice and 12 hours later the 
serum C-terminal FGF23 (cFGF23) levels determined. As illustrated in Fig. 1A, the injection of 
DOCA was followed by a marked and significant increase in the serum cFGF23 concentration. 
In a second series of experiments, mice were fed a low salt diet. As expected, this diet induced 
an elevation of the serum aldosterone level (889 ± 217 pg/ml; n=5) compared to standard 
chow-fed mice (268 ± 27 pg/ml; n=5; p<0.01). The diet did not significantly affect the serum 
corticosterone level (low salt diet: 162 ± 32 ng/ml; n=5; standard chow: 120 ± 31 ng/ml; n=5). 
As illustrated in Fig 1B, the low salt diet elevated the serum concentration of C-terminal 
FGF23. The main site of FGF23 formation is the bone. Accordingly, we found a higher level of 
Fgf23 transcripts in bone from DOCA-treated mice compared to untreated mice (Fig. 1C). 
Treatment with spironolactone (12 h, 75 mg/kg b.w.) did, however, not significantly influence 
the serum FGF23 concentration (control: 201 ± 6 pg/ml, n=5; spironolactone: 332 ± 65 pg/ml, 
n=5). Similarly, spironolactone treatment did not block the increase in serum FGF23 induced 
by low-salt diet (serum FGF23 before low-salt diet: 134 ± 15 pg/ml; serum FGF23 after two 
weeks of low-salt diet: 194 ± 13 pg/ml; n=8; p<0.01). 
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The next series of experiments explored whether Ca2+ release-activated Ca2+-channel 
(CRAC) moiety Orai1 and its regulator STIM1 are expressed in osteoblastic cells and therefore 
participate in the signaling regulating FGF23 formation in those cells. Experiments were thus 
performed in UMR106 osteoblast-like cells and in immortalized primary periosteal cells (IPO). As 
illustrated in Fig.2A, Orai1 was expressed in UMR106 and IPO cells as well as in bone. 
Moreover, Orai3 and STIM2 transcripts could be readily detected in UMR106 cells whereas the 
abundance of Orai2 and Stim1 was low (Fig. 2B). Orai1 transcript levels were reduced following 
inhibition of NFκB by wogonin in UMR106 cells (Fig. 2C). 
 Fluorescence optics was employed to explore whether Orai1 and/or NFκB impact on 
intracellular Ca2+ concentration ([Ca2+]i). Store-operated Ca2+ entry (SOCE) requires depletion of 
intracellular Ca2+ stores which was accomplished by inhibition of the sarcoendoplasmic Ca2+ 
ATPase (SERCA) with thapsigargin (1 µM) in the absence of extracellular Ca2+. SOCE was 
estimated from the increase in [Ca2+]i following re-addition of extracellular Ca2+. As illustrated in 
Fig. 3A,D,G,J, thapsigargin (10 µM) treatment in the absence of extracellular Ca2+ was followed 
by a transient elevation of [Ca2+]i reflecting depletion of intracellular stores. The subsequent 
addition of extracellular Ca2+ was followed by a rapid increase in [Ca2+]i reflecting store-operated 
Ca2+ entry (SOCE). Addition of Orai1 inhibitors 2-APB (Fig. 3A-C) or YM58483 (Fig. 3D-F) did 
not significantly modify the thapsigargin-induced increase in [Ca2+]i but virtually abrogated the 
increase in [Ca2+]i following re-addition of extracellular Ca2+. Similarly, Orai1 silencing did not 
significantly modify the thapsigargin-induced increase in [Ca2+]i but significantly blunted the 
increase in [Ca2+]i following re-addition of extracellular Ca2+ (Fig. 3G-I). Exposure of UMR106 
cells to wogonin significantly blunted the thapsigargin-induced increase in [Ca2+]i and the increase 
in [Ca2+]i following re-addition of extracellular Ca2+ (Fig. 3J-L). Similarly, the NFκB inhibitor 
CAS 545380-34-5 decreased Orai1 transcript levels, the thapsigargin-induced increase in [Ca2+]i  
and SOCE in UMR106 cells (suppl. Fig. 1A and C).  
 Next, RT-PCR was employed to determine whether Ca2+ entry and/or NFκB influences 
the formation of FGF23. As illustrated in Fig, 4, Fgf23 transcript levels were significantly 
increased by the Ca2+ ionophore ionomycin (Fig. 4A) and by thapsigargin (Fig. 4B). 
Conversely, blocking Ca2+ entry by the Orai blockers 2-ABP (Fig. 4C), YM58483 (Fig. 4D), or 
SK&F96365 (Fig. 4E) decreased the abundance of Fgf23 transcripts. In view of the limited 
specificity of the Orai1 blockers, additional experiments were performed with silencing of 
Orai1. As illustrated in Fig. 4F, silencing of Orai1 also lowered FGF23 transcript levels in 
UMR106 cells. We could, however, not confirm a significant decrease of Orai1 protein 
abundance following Orai1 silencing (data not shown). Nevertheless, steady-state FGF23 
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production in UMR106 cells was dependent on [Ca2+]i which was modified by Ca2+ entry. In 
contrast, L-type calcium channel inhibitors did not appreciably influence FGF23 transcript 
levels. The Fgf23 transcript level was 0.019 ± 0.004 a.u. in control cells (n=9) and 0.018 ± 
0.003 a.u. (n=9) in cells treated with L-type channel inhibitor nifedipine (100 µM, 24 h). In 
another series, the Fgf23 transcript level was 0.011 ± 0.001 a.u. (n=9) in control cells and 0.011 
± 0.001 a.u. (n=9) in cells treated with L-type channel inhibitor verapamil (10 µM, 24 h).  
Since Ca2+ entry into UMR106 cells could be attenuated by the NFκB inhibitor wogonin 
(Fig. 3J-L), we tested whether FGF23 formation is also NFκB-sensitive. Indeed, Fgf23 
transcript levels were reduced by the NFκB inhibitors wogonin (Fig. 5A) and withaferin A (Fig. 
5B). The NFκB inhibitor CAS 545380-34-5 also decreased FGF23 transcript levels (suppl. Fig 
1B). 
Since the level of confluence has been shown to affect FGF23 production in primary 
osteoblasts [35], we preformed experiments at different stages of confluency. In a culture of 
300,000 UMR106 cells, the FGF23 transcript levels were significantly (p<0.01) higher in 
control cells (0.029 ± 0.005 a.u., n=12) than in cells exposed 24 hours to 100 µM wogonin 
(0.009 ± 0.001 a.u., n=12). In a culture of 200,000 UMR106 cells, the FGF23 transcript level 
were again significantly (p<0.001) higher in control cells (0.012 ± 0.001 a.u., n=12) than in 
cells exposed for 24 hours to 100 µM wogonin (0.004 ± 0.000 a.u., n=12). Finally, in a culture 
of 100,000 UMR106 cells, the FGF23 transcript level was again significantly (p<0.01) higher 
in control cells (0.006 ± 0.001 a.u., n=12) than in cells exposed 24 hours to 100 µM wogonin 
(0.002 ± 0.000 a.u., n=12). Thus, the level of confluence influenced the basal FGF23 transcript 
level but did not affect the inhibitory effect of wogonin on FGF23 formation. 
 To test whether aldosterone influences Ca2+ signaling, UMR106 cells were treated with 
aldosterone or the mineralocorticoid receptor antagonist spironolactone and intracellular Ca2+ 
concentrations ([Ca2+]i) were determined prior to and following removal of extracellular Ca2+, 
addition of thapsigargin, and re-addition of extracellular Ca2+. As illustrated in Fig. 6A-C, 
aldosterone did not significantly modify the thapsigargin-induced increase in [Ca2+]i but 
significantly enhanced the elevation of [Ca2+]i following re-addition of extracellular Ca2+. 
Conversely, spironolactone did not significantly modify the thapsigargin-induced increase in 
[Ca2+]i either, but significantly blunted the increase in [Ca2+]i following re-addition of 
extracellular Ca2+ (Fig. 6D-F). 
 A final series of experiments explored whether the influence of aldosterone and 
spironolactone on Ca2+ signaling in UMR106 cells was involved in the transcriptional 
regulation of Fgf23. Aldosterone (Fig. 7A) significantly elevated the Orai1 transcript level in 
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UMR106 cells. Moreover, aldosterone up-regulated the transcription of Fgf23, an effect 
virtually abrogated by spironolactone, the Orai inhibitor YM58483, or the NFκB inhibitor 
withaferin A (Fig. 7B). The dose-response curve of the aldosterone effect on FGF23 is shown in 
Fig 7C. The aldosterone antagonist eplerenone similarly reversed the aldosterone effect on 
Fgf23 (Fig. 7D). Immunofluorescence confirmed activation of NFκB by aldosterone in 
UMR106 cells (Fig. 7E).  
 A possible mediator of the aldosterone effect on Orai1 is SGK1 which has been shown to 
up-regulate this channel. Employing qRT-PCR we indeed found a positive effect of aldosterone 
on the Sgk1 transcript level in UMR106 cells (control: 0.73 ± 0.04 a.u., n=12; 100 nM 
aldosterone: 1.02 ± 0.05 a.u.,n=12; p<0.001). Moreover, aldosterone failed to stimulate FGF23 
expression in the presence of a SGK1 inhibitor (Fig. 7F). 
 The dose effects of mineralocorticoid antagonism with spironolactone or eplerenone are 
displayed in Fig. 8A and 8B, respectively. Notably, the effect of higher aldosterone concentrations 
on FGF23 transcription were also blocked by the glucocorticoid antagonist mifepristone (Fig. 8C). 
 
   
Discussion 
 
 The present observations reveal that mineralocorticoids may contribute to the regulation of 
FGF23 transcription and release. Furthermore, they disclose a decisive role of the cytosolic Ca2+ 
concentration ([Ca2+]i) for the regulation of FGF23 release. Store operated Ca2+ entry (SOCE) 
apparently stimulated the transcription of Fgf23. SOCE is accomplished by the pore-forming Orai 
(CRAC) isoforms [30] and their regulators STIM1 and STIM2  [31]. According to the present 
observations, Orai1 and STIM2 are both highly expressed in osteoblastic UMR106 cells. Orai1 
expression has been shown to be up-regulated by the transcription factor NFκB [32]. Our study 
demonstrates that in UMR106 cells inhibition of NFκB reduced Orai1 transcript levels. Moreover, 
Fgf23 expression was also down-regulated by NFκB inhibitors. Aldosterone has previously been 
shown to up-regulate NFκB [33, 36]. The present study reveals that the effect of aldosterone is 
abrogated by NFκB inhibitors. The present observations do, however, not rule out that NFκB 
plays a permissive role in the regulation of FGF23 expression and release.  Moreover, we cannot 
rule out that Ca2+ entry mechanisms other than Orai1 are involved in the stimulation of FGF23 
transcription.   
 As aldosterone is effective at concentrations as low as 1 nM, the effect of aldosterone is 
most likely in part due to stimulation of mineralocorticoid receptors. The effect of higher 
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aldosterone concentrations is, however, blunted by the glucocorticoid antagonist mifepristone, an 
observation pointing to effects of glucocorticoid receptors. Noteworthy, both, mineralocorticoid 
and glucocorticoid receptors upregulate the serum & glucocorticoid inducible kinase (SGK1) 
which has been shown to upregulate Orai1 dependent Ca2+ entry by activating NFκB [37]. Along 
those lines, pharmacological SGK1 inhibition reversed the effect of aldosterone on FGF23 
expression. Spironolactone treatment, however, did not reverse the increase in serum FGF23 
induced by low-salt diet. Thus, the possibility must be kept in mind that mechanisms other than 
mineralocorticoid receptor activation contribute to the up-regulation of FGF23 release during 
dehydration. Along those lines, renal klotho expression is not only down-regulated by 
mineralocorticoids but as well by ADH [38].  
Chronic kidney disease [39-41], heart failure [42-44], diabetic nephropathy [45] and 
hepatic failure [44] are all characterized by hyperaldosteronism. According to the present 
observations, the high FGF23 plasma concentration in heart failure [16, 17], acute renal failure 
[18], chronic kidney disease [7, 17, 19], diabetic nephropathy [20] and hepatic failure [21] 
could at least in part be secondary to the hyperaldosteronism associated with those diseases. 
Orai1 is up-regulated by the SGK1 [32], which is in turn markedly up-regulated by aldosterone 
and during diabetes [46].  
FGF23 is further high in polycystic kidney disease [14]. It is therefore tempting to 
speculate that the excessive FGF23 plasma level in polycystic kidney disease results from 
NFκB-dependent up-regulation of Orai1. FGF23 levels are also high in gene targeted mice 
expressing WNK-resistant SPAK [47] or OSR1 [48] an effect possibly also due to renal sodium 
wasting and thus increased release of aldosterone.  
The FGF23 and aldosterone serum level is further elevated in Klotho-deficient mice [12, 
13]. According to the present observations, the hyperaldosteronism of those mice could 
contribute to excessive FGF23 formation. It should be pointed out, however, that the FGF23 
level is most likely in large part due to stimulation of FGF23 formation by high 1,25(OH)2D3.  
The regulation of FGF23 formation by NFκB and Ca2+ entry is expected to influence 
mineral metabolism. FGF23 down-regulates renal 1α hydroxylase expression and thus the 
formation of 1,25(OH)2D3 [49, 50] as it requires αKlotho as a co-receptor for its effect on 
1,25(OH)2D3 formation [8]. 1,25(OH)2 D3 is known to stimulate both, renal and intestinal 
phosphate transport [5]. Moreover, FGF23 reduces renal tubular phosphate reabsorption more 
directly by inhibiting proximal tubular Na+-coupled phosphate transport [50]. FGF23 thus 
fosters phosphaturia and hypophosphatemia. In chronic kidney disease hyperphosphatemia 
results in vascular calcifications [51] and both, Klotho and FGF23 counteract those 
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calcifications [39]. As a high serum phosphate concentration triggers vascular calcifications 
and is associated with accelerated aging and a decreased life span [52], high FGF23 plasma 
levels protect against vascular calcifications, aging and early death. Along those lines, αKlotho 
[53] and FGF23 [54] counteract aging and lack of either, αKlotho [53] or FGF23 [50] fosters 
early appearance of multiple age-related disorders leading to early death. 1,25(OH)2D3 
stimulates the release of FGF23 [24] and thus triggers a negative feedback loop limiting 
1,25(OH)2D3 formation. 
 The pathophysiological impact of elevated FGF23 plasma levels is still ill-defined. 
While a high FGF23 plasma level is associated with high morbidity and mortality in heart and 
kidney failure [16-18], FGF23 neutralization increases the mortality of rats with chronic kidney 
disease-mineral and bone disorder [55]. In view of the present observations it is tempting to 
speculate that the association between the FGF23 plasma level and morbidity and mortality 
reflects the stimulating effect of aldosterone and/or NFκB on inflammation on the one side and 
FGF23 formation on the other, thus affecting both, FGF23 plasma level and disease 
progression. 
In conclusion, the present observations disclose a novel mechanism regulating FGF23 
release. FGF23 formation in UMR106 cells is stimulated by an increased cytosolic Ca2+ 
concentration, which is regulated by store operated Ca2+ entry (SOCE). SOCE and FGF23 
formation are up-regulated by the transcription factor NFκB. Aldosterone up-regulates FGF23 
by NFκB and SOCE sensitive cellular mechanisms.  
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Figure Legends 
 
Fig. 1. Effect of aldosterone on the FGF23 serum level  
A. Arithmetic means ± SEM (n=9-11) of serum FGF23 concentrations in wild type mice 
sham-treated (white bar) or treated with a single DOCA injection (100 mg/kg b.w. s.c.) for 12 
hrs (black bar).  
B. Arithmetic means ± SEM (n=11) of serum FGF23 concentrations in wild type mice treated 
with normal diet (white bar) or with low salt diet for 14 days (black bar).  
C. Arithmetic means ± SEM (n=4-5) of the relative Fgf23 mRNA abundance in wild type mice 
sham-treated (white bar) or treated with a single DOCA injection (100 mg/kg b.w. s.c.) for 12 
hrs (black bar). *(p<0.05), **(p<0.001), ***(p<0.001), indicate significant difference.   
 
 
Fig. 2 Expression of Orai1 in bone, osteoblasts, UMR106 cells, and the effect of NFκB 
inhibitor wogonin 
A. Original Western blots showing the protein expression of Orai1 (1st lane) and GAPDH (2nd 
lane), in UMR106 cells (UMR), immortalized primary periosteal cells (IPO) and bone.  
B. Original 2% agarose gel showing specific amplification of Orai1 (357 bp), Orai2 (292 bp), 
Orai3 (328 bp), Stim1 (163 bp), Stim2 (298 bp) and Tbp (91 bp) cDNA in UMR106 cells. 
C. Arithmetic means ± SEM (n=9) of Orai1 mRNA abundance (relative to Tbp mRNA) in 
UMR106 cells incubated without (white bar) or with (black bar) NFκB inhibitor wogonin (100 
µM, 48 h). ***(p<0.001), indicate significant difference 
 
Fig. 3. Effect of 2-APB, YM58483, Orai1 silencing, and wogonin on SOCE in UMR106 cells  
A,D,J. Representative original tracings showing intracellular Ca2+ concentrations ([Ca2+]i) in 
Fura-2/AM loaded UMR106 cells prior to and following removal of extracellular Ca2+, addition of 
the sarco-endoplasmic Ca2+ ATPase (SERCA) inhibitor thapsigargin (1 µM) and readdition of 
extracellular Ca2+, all in the absence (open circles) and presence (closed circles) of Orai inhibitor 
2-APB (A, 50 µM), Orai inhibitor YM58483 (D, 100 nM), or NFκB inhibitor wogonin (J, 100 
µM, 48 h). 
B,C,E,F,H,I. Arithmetic means ± SEM of the peak (left) and slope (right) values of [Ca2+]i 
increase following addition of thapsigargin reflecting Ca2+ release from intracellular stores 
(B,E,K) and of [Ca2+]i increase following readdition of extracellular Ca2+ reflecting store operated 
Ca2+ entry (C,F,L) in UMR106 cells incubated without (white bars) or with (black bars) Orai 
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inhibitor 2-APB (B-C, 50 µM, n=22-60), or with the Orai inhibitor YM58483 (E-F, 100 nM, 
n=40-39) or the NFκB inhibitor wogonin (K-L, 100 µM, 48 h, n=12-31), 
G. Representative original tracings showing intracellular Ca2+ concentrations ([Ca2+]i) in 
Fura-2/AM loaded UMR106 cells prior to and following removal of extracellular Ca2+, addition of 
the sarco-endoplasmic Ca2+ ATPase (SERCA) inhibitor thapsigargin (1 µM) and readdition of 
extracellular Ca2+, all in cells treated with unspecific siRNA (open circles) or with specific siRNA 
targeting Orai1 (closed circles). 
H,I. Arithmetic means ± SEM of the peak (left) and slope (right) values of [Ca2+]i increase 
following addition of thapsigargin reflecting Ca2+ release from intracellular stores (H) and of 
[Ca2+]i increase following readdition of extracellular Ca2+ reflecting store operated Ca2+ entry (I) 
in UMR106 cells treated with unspecific siRNA (white bars) or with specific siRNA targeting 
Orai1 (black bars).**(p<0.001), ***(p<0.001), indicate significant difference.   
 
Fig. 4. Effect of ionomyin, thapsigargin, 2-APB, YM58483, SK&F96365, and Orai1 
silencing on FGF23 transcript levels in UMR106 cells  
Arithmetic means ± SEM of Fgf23 mRNA abundance (relative to Tbp mRNA) in UMR106 
cells incubated without (white bars) or with (black bars) ionomycin (A, 100 nM, 2 h, n=12), 
thapsigargin (B, 500 nM, 2 h, n=12), the Orai inhibitor 2-ABP (C, 50 µM, 24, n=6), the Orai 
inhibitor YM58483 (D, 100 nM, 24 h, n=15) and the Orai inhibitor SK&F96365 (E, 10 µM, 24 
h, n=16-19).  
F. Arithmetic means ± SEM (n=16) of Fgf23 mRNA abundance (relative to Tbp mRNA) in 
UMR106 cells treated with control siRNA (siNeg, white bar) or with specific Orai1 siRNA 
(siOrai1, black bar).*(p<0.05), **(p<0.001), ***(p<0.001) indicate significant difference 
(t-test).   
 
Fig. 5. Effect of wogonin and withaferin A on Fgf23 transcript levels in UMR106 cells  
Arithmetic means ± SEM of Fgf23 mRNA abundance (relative to Tbp mRNA) in UMR106 
cells incubated without (white bars) or with (black bars) wogonin (A, 100 µM, 48 h, n=8-9) and 
withaferin A (B, 500 nM, 24 h, n=15-20).**(p<0.001), ***(p<0.001) indicate significant 
difference (t-test).   
 
Fig. 6. Effect of aldosterone and spironolactone on SOCE  
A,D. Representative original tracings showing intracellular Ca2+ concentrations ([Ca2+]i) in 
Fura-2/AM loaded UMR106 cells prior to and following removal of extracellular Ca2+, addition of 
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the sarco-endoplasmic Ca2+ ATPase (SERCA) inhibitor thapsigargin (1 µM) and readdition of 
extracellular Ca2+, all in the absence (open circles) and presence (closed circles) of aldosterone (A, 
100 nM, 24 h), or spironolactone (D, 10 µM, 24 h). 
B,C,E,F. Arithmetic means ± SEM of the peak (left) and slope (right) values of [Ca2+]i increase 
following addition of thapsigargin reflecting Ca2+ release from intracellular stores (B,E) and of 
[Ca2+]i increase following readdition of extracellular Ca2+ reflecting store operated Ca2+ entry 
(C,F) in UMR106 cells incubated without (white bars) or with (black bars) aldosterone (B-C, 100 
nM, 24 h, n=72-80), or spironolactone (E-F, 10 µM, 24 h, n=121-133).*(p<0.05), ***(p<0.001) 
indicate significant difference (t-test).   
 
Fig.7. Effect of aldosterone on FGF23 transcript levels in UMR106 cells with or without 
presence of spironolactone, eplerenone, YM58483 and withaferin A  
A. Arithmetic means ± SEM (n=18) of Orai1 mRNA abundance (relative to Tbp mRNA) in 
UMR106 cells incubated without (white bar) or with (black bar) aldosterone (100 nM, 24 h). 
B. Arithmetic means ± SEM (n=7) of FGF23 mRNA abundance (relative to Tbp mRNA) in 
UMR106 cells incubated without (white bars) or with (black bars) aldosterone (100 nM, 6 h) in 
the absence (left bars) or presence (right bars) of spironolactone (10 µM) of Orai inhibitor 
YM58483 (100 nM) or of NFκB inhibitor withaferin A (500 nM). 
C. Arithmetic means ± SEM (n=36-37) of FGF23 mRNA abundance (relative to Tbp mRNA) 
in UMR106 cells incubated without (white bars) or with (black bars) aldosterone (6 h) at the 
indicated concentration. 
D. Arithmetic means ± SEM (n=11) of FGF23 mRNA abundance (relative to Tbp mRNA) in 
UMR106 cells incubated without (white bars) or with (black bars) aldosterone (100 nM, 6 h) in 
the absence (left bars) or presence (right bars) of eplerenone (10 µM). 
E. Original immunofluorescence images demonstrating nuclear staining (Draq5; Red; left 
images), p65-specific staining (NFκB; Green middle images), and an overlay of both, nuclear 
and p65-specific staining (right images) in UMR106 cells incubated without (upper images) or 
with (lower images) aldosterone (100 nM, 24 h) Scale bar: 20 μm. 
F. Arithmetic means ± SEM (n=12) of FGF23 mRNA abundance (relative to Tbp mRNA) in 
UMR106 cells incubated without (white bars) or with (black bars) aldosterone (100 nM, 6 h) in the 
absence (left bars) or presence (right bars) of SGK1 inhibitor EMD638683 (50 µM). 
*, **, *** (p<0.05, p<0.01, p<0.001) indicate difference from control. ### (p<0.001) indicates 
difference from aldosterone alone. 
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Fig.8. Dose response relationship of mineralocorticoid and glucocorticoid antagonism with 
the aldosterone effect on FGF23 transcription 
Arithmetic means ± SEM of FGF23 mRNA abundance (relative to Tbp mRNA) in UMR106 
cells incubated with spironolactone (A; n=15), eplerenone (B; n=9-11), or mifepristone (C; n= 
4-6) at the indicated concentration without (white bars) or with (black bars) 100 nM aldosterone 
(6 h).  
*, ** (p<0.05, p<0.01) indicate difference from control. #, ### (p<0.05, p<0.001) indicate 
difference from aldosterone alone. 
 








 Suppl. Fig 1. NFκB inhibitor CAS 545380-34-5 lowers Orai1 and FGF23 transcript levels 
as well as SOCE in UMR106 cells  
A. Arithmetic means ± SEM (n=6) of Orai1 mRNA abundance (relative to Tbp mRNA) in 
UMR106 cells incubated without or with NFκB inhibitor CAS 545380-34-5 (100 nM, 24 h). 
B. Arithmetic means ± SEM (n=6) of FGF23 mRNA abundance (relative to Tbp mRNA) in 
UMR cells incubated without or with NFκB inhibitor CAS 545380-34-5 (100 nM, 24 h). 
C. Representative original tracings (left panel) showing intracellular Ca2+ concentrations 
([Ca2+]i) in Fura-2/AM loaded UMR106 cells prior to and following removal of extracellular 
Ca2+, addition of the sarco-endoplasmic Ca2+ ATPase (SERCA) inhibitor thapsigargin (1 µM) 
and readdition of extracellular Ca2+ in the absence (open circles) and presence (closed circles) of 
the NFκB inhibitor CAS 545380-34-5 (100 nM, 24 h). The upper right panel depicts the 
arithmetic means ± SEM (n=45-72) of the peak (left) and slope (right) values of [Ca2+]i increase 
following addition of thapsigargin reflecting Ca2+ release from intracellular stores and the lower 
right shows the arithmetic means ± SEM (n=45-72) of the peak (left) and slope (right) values of 
[Ca2+]i increase following readdition of extracellular Ca2+ reflecting store operated Ca2+ entry in 
UMR106 cells incubated without (white bars) or with (black bars) NFκB inhibitor CAS 545380-
34-5 (100 nM, 24 h). 
**(p<0.01), ***(p<0.001) indicate significant difference (t-test). 
